A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Moderate to Severe Asthma Clinical Trial

Official title:
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Status Recruiting

Clinical Trial Summary

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05851443
Study type	Interventional
Source	Incyte Corporation
Contact	Incyte Corporation Call Center (US)
Phone	1.855.463.3463
Email	medinfo@incyte.com
Status	Recruiting
Phase	Phase 2
Start date	July 11, 2023
Completion date	August 8, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03556683` - Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics	N/A
Recruiting	`NCT05774340` - A Study of CM326 in Subjects With Moderate to Severe Asthma	Phase 2
Recruiting	`NCT06385236` - Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping	Phase 4
Completed	`NCT05062759` - Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma	Phase 3
Completed	`NCT04307173` - Study of Multiple Ascending Dose of KBL693 in Healthy Participants	Phase 1
Recruiting	`NCT05761028` - A Study of CM310 in Subjects With Moderate to Severe Asthma	Phase 2/Phase 3